• Alias: IMC-1121B
    • A recombinant, fully human mAb directed against VEGFR-2. Has a high affinity for VEGFR2, binding to it and blocking the binding of VEGFR ligands VEGF-A, VEGF-C, and VEGF-D to inhibit the activation of VEGFR2, thereby inhibiting ligand-induced proliferation and migration of endothelial cells. VEGFR2 inhibition results in reduced tumor vascularity and growth.
    • FDA approved for mCRC, advanced or metastatic gastric cancer, metastatic NSCLC
    • Recommended dose: 8 mg/kg IV every 2 weeks (colorectal and gastric cancer); 10 mg/kg IV every 21 days (NSCLC)
    • Half-life: 14 days
    • Common side effects: Nausea/vomiting, he, fatigue, proteinuria, hypertension, abdominal pain, DVT
    Other topics in Targeted and Immunotherapy Agents